Condition: Advanced Solid Tumors · HER2 Mutation · Sponsor: Bayer
Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it works. In this trial, the researchers want to learn how well BAY2927088 (sevabertinib) works in people with different types of solid tumors with HER2 mutations. These include tumors in the colon or rectum, the uterus and the cervix (lower part of the uterus), the breast, the bladder, and the biliary tract (includes gall bladder and bile ducts) as well as other types of solid tumors with the exception of people with advanced non-small cell lung cancer (NSCLC). Solid tumors may have specific changes or mutations to a gene called human epidermal growth receptor-2 (HER2). This leads to the formation of an abnormal form of HER2 protein in the cancer cells, resulting in increased cell growth. The study treatment, BAY2927088, is expected to block the abnormal HER2 protein which may stop the spread of cancer. The trial will include about 111 participants who are at least 18 years old. All the participants will take 20 mg of BAY2927088 as tablets by mouth. The participants will take treatments in 3-week periods called cycles. These 3-week cycles will be repeated throughout the trial. The participants can take BAY2927088 until their cancer gets worse, until they have medical problems, or until they leave the trial. During the trial, the doctors …
This description comes directly from the study's public registry record.
Bayer Clinical Trials Contact · (+)1-888-84 22937 · clinical-trials-contact@bayer.com
Always discuss trial participation with your own doctor first.
| UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital | Birmingham, Alabama, United States | Recruiting |
| City of Hope - Duarte Cancer Center | Duarte, California, United States | Recruiting |
| Florida Cancer Specialists & Research Institute - Fort Myers Cancer Center - Gladiolus | Fort Myers, Florida, United States | Recruiting |
| Dana-Farber Cancer Institute - Oncology Department | Boston, Massachusetts, United States | Recruiting |
| Brigette Harris Cancer Pavilion at Henry Ford Cancer Center - Detroit | Detroit, Michigan, United States | Withdrawn |
| Profound Research -OMG - TriAtria Cancer Center | Farmington Hills, Michigan, United States | Recruiting |
| Cleveland Clinic - Oncology Department | Cleveland, Ohio, United States | Recruiting |
| SCRI Oncology Partners | Nashville, Tennessee, United States | Recruiting |
| The University of Texas MD Anderson Cancer Center - Texas Medical Center | Houston, Texas, United States | Recruiting |
| Gynecology Oncology clinic at UW Medical Center - Montlake | Seattle, Washington, United States | Withdrawn |
| UW Health Carbone Cancer Center | Madison, Wisconsin, United States | Recruiting |
| NSW Health - Blacktown Hospital | Blacktown, New South Wales, Australia | Recruiting |
+ 42 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06760819